The Global Coalition on Aging Applauds FDA for New Draft Alzheimer’s Guidance

New guidance provides clarity on endpoints, will help spur pharmaceutical innovation for Alzheimer’s treatments

NEW YORK, NY (17 May 2018) – The Global Coalition on Aging (GCOA) today submitted comments to the U.S. Food & Drug Administration (FDA) supporting the administration’s new regulatory guidance document on early Alzheimer’s disease and calling for similar updates for related dementias. The draft guidance clarifies the clinical endpoints required for early Alzheimer’s disease treatments, reflecting the latest understanding of the disease’s progression, and opening opportunities for increased pharmaceutical innovation.

“By issuing this new draft guidance, the FDA has demonstrated its commitment to rapidly advancing innovation in Alzheimer’s drug development,” said Michael Hodin, CEO of the Global Coalition on Aging. “As Alzheimer’s affects more and more of us across society as the population ages, researchers and regulators alike must adapt based on what the science has taught us. We applaud the FDA for its leadership in recognizing the urgency to update regulations and create a path for faster and smarter processes that remove barriers to innovation.”

GCOA is also calling for the FDA to make advancements in clinical trial enrollment: first, by developing common diagnostic criteria for enrollment in clinical trials. Secondly, GCOA is recommending more aggressive focus on earlier detection and diagnosis to help ensure adequate participation from people with Alzheimer’s in clinical trials. By collecting data earlier in the progression of dementia, researchers can pinpoint drug targets more effectively and efficiently.

GCOA’s comments are in line with findings from the Dementia Innovation Readiness Index,a collaborative report published by GCOA and Alzheimer’s Disease International (ADI) in 2017. It analyzed the readiness of different countries to integrate innovative solutions for dementia treatment, prevention and care into their healthcare and policy systems. In 2017, the Index focused on the G7 countries – Canada, France, Germany, Italy, Japan, and the United Kingdom. In 2018, the Index will expand to focus on select G20 countries – Argentina, Brazil, China, India, and Saudi Arabia. The 2018 edition of the Index will be released at ADI’s annual conference in Chicago this July.

Latest Developments

We keep our members and partners in touch with the most recent updates and opinions in the worldwide dialogue on population longevity and related issues.

What Old Age Might Be Like for Today’s 30-Year-Olds

Get ready for a new old age. With the U.S. fertility rate in a decadelong slump and the life expectancy of 65-year-old Americans approaching roughly 85, our aging nation is likely to grow older by midcentury, as the ratio of young to old continues to decline. The trend is likely to upend how our society is organized, making life very different for today’s 30-year-olds when they reach their 60s compared with life for 60-year-olds now.

World Population Reaches 8bn As It Grows Older

The world’s population reached 8bn people on Tuesday and will hit 9bn in 15 years as it experiences an unprecedented surge in the number of older people, according to the latest UN data. The global fertility rate has more than halved since the 1950s to 2.3 births per woman. With mortality also falling, the number of people aged 65 and over is expected to rise from 783mn in 2022 to 1bn by 2030 and reach 1.4bn by 2043, the UN population data revealed.

Global Coalition on Aging (GCOA) Launches Cross-Sector Alliance Committed to Health Innovation at High-Level Forum on The Silver Economy

Today, the Global Coalition on Aging (GCOA), along with cross-sector stakeholders representing patient advocacy, policy, industry, and academic communities, announced the launch of the Alliance for Health Innovation at the High-Level Forum on the Silver Economy in New York. The Alliance is dedicated to establishing the importance of innovation in achieving healthy aging and health equity through investments, policy reforms, and strategic partnerships.

Japan Must Face Up to Growing Danger of Drug-resistant Germs

In the wake of more than 6.4 million COVID-19 deaths worldwide and unprecedented economic destruction, the global community has no excuse to be caught unprepared for the next pandemic. Yet right now, a devastating parallel plague is already underway and worsening. Some years, it is killing well over 1 million people, according to medical journal The Lancet.

A Bipartisan Bill Could Prevent The Next Pandemic

In Washington, Republicans and Democrats are typically at loggerheads when it comes to healthcare policy. Just consider the recent Inflation Reduction Act, which made extensive changes to Medicare and also extended Affordable Care Act subsidies. Every single congressional Democrat voted for the legislation, while every single member of the GOP voted against it. But occasionally, a bill is such an obviously good idea, and so desperately needed, that it commands significant bipartisan support. The PASTEUR Act, co-sponsored by 31 Democrats and 31 Republicans in the House and two members of each party in the Senate, is just such a bill.

Korea Must Act Now to Combat Growing AMR Threat

Public officials are overlooking one of the gravest long-term threats to the Korean people, the health system, and economy: antimicrobial resistance (AMR). Some pathogens ― bacteria, fungi, parasites, and viruses ― have evolved strains that resist the antimicrobial medications we currently have available to fight them. Health care professionals often must watch helplessly as patients succumb to infections that antibiotics could once have easily beaten. They know that new antimicrobials, including and especially antibiotics, could easily gain the victory ― but they have none at their disposal.

Policy Statement on the Impact of Price Negotiations on Innovation, Healthy Aging and Equity

As the CEO of the Global Coalition on Aging (GCOA) and a newly formed cross-sector Alliance for Health Innovation, we write to express our deep concern with the current legislation that allows for price “negotiations” in Medicare – a thinly veiled signal for America’s plunge into price controls that will have a devastating and adverse impact on biopharmaceutical innovation and our nations’ ability to support healthy aging.